Suppr超能文献

使用新型止血剂行内镜逆行胰胆管造影术中即时出血的内镜处理。

Endoscopic Management Using Novel Haemostatic Agents for Immediate Bleeding during Endoscopic Retrograde Cholangio-Pancreatography.

机构信息

Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia.

Digestive Disease & GI Oncology Center, Medistra Hospital, Jakarta, Indonesia.

出版信息

Can J Gastroenterol Hepatol. 2023 Apr 10;2023:5212580. doi: 10.1155/2023/5212580. eCollection 2023.

Abstract

Bleeding after endoscopic sphincterotomy (ES) remains as a major challenge during ERCP procedure. Standard endoscopic haemostatic procedures have demonstrated good performance for bleeding control. Novel endoscopic haemostatic agents have also been widely used in gastrointestinal bleeding management. Regardless, there is still a paucity of high-quality evidence evaluating the practicality of these agents in ERCP. This case series study was performed on the patients who underwent ERCP procedure in a tertiary referral private hospital within 2 years period. Post-ES immediate bleeding is defined as the onset of bleeding at the time of sphincterotomy. Treatment groups for post-ES bleeding are divided into (1) standard haemostatic methods and (2) novel haemostatic agents. There were 40 patients who received standard haemostatic treatment and 60 patients who received novel haemostatic agents. Initial haemostasis was achieved in all patients. Two patients who received standard haemostatic treatment had rebleeding. Meanwhile, no patients in novel haemostatic treatment group had rebleeding. In conclusion, novel haemostatic agent can be considered as an easy and practical method in daily practice, especially when an ERCP procedure is performed. Further studies with larger sample size which, if possible, can also include a cost-effectiveness analysis are still required to implement these agents as a standard procedure in clinical practice. (This abstract has been presented at the American College of Gastroenterology meeting October 2021).

摘要

经内镜括约肌切开术(ES)后出血仍然是 ERCP 过程中的主要挑战。标准的内镜止血程序已证明对控制出血有良好的效果。新型内镜止血剂也已广泛用于胃肠道出血的治疗。然而,仍然缺乏高质量的证据来评估这些药物在 ERCP 中的实用性。本病例系列研究是在 2 年内对一家三级私立医院接受 ERCP 治疗的患者进行的。ES 后即刻出血定义为括约肌切开时出血的开始。ES 后出血的治疗组分为(1)标准止血方法和(2)新型止血剂。有 40 名患者接受标准止血治疗,60 名患者接受新型止血剂治疗。所有患者均达到初始止血。2 名接受标准止血治疗的患者再次出血。而新型止血剂治疗组无患者再出血。总之,新型止血剂在日常实践中可以被认为是一种简单实用的方法,尤其是在进行 ERCP 时。需要进一步进行更大样本量的研究,如果可能的话,还包括成本效益分析,以将这些药物作为临床实践中的标准程序实施。(本摘要已在 2021 年 10 月美国胃肠病学会会议上发表)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fec/10110383/ca2d89729afe/CJGH2023-5212580.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验